Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Bausch Health Companies Inc BHC


Primary Symbol: T.BHC

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with... see more

TSX:BHC - Post Discussion

View:
Post by 5to10hold on May 27, 2021 12:15pm

B&L Spin Out

This is just pure speculation, but I'm wondering if B&L is Pershing Square Tontine Holdings target that they have been working on since November. Some thoughts below: 

- "Iconic" Business per Ackman comments - check (it's been around for over 100 years)
- Per Ackman's comments, "a lot of complexity and solving an issue" - check (B&L is being spun out of Bausch Health with proceeds being used to repay debt; BHC needs to internally organize to stand-up B&L on its own; BHC; B&L would otherwise be spun out via IPO).
- Timing (working on it since November) - check (fits well with timing on BHC disclosures on spinning out B&L; BHC is rumoured to have solicited offers for B&L which were due mid April so they have had time to evaluate; B&L would be ready for a spin-out by Q3 per management guidance)

-Strong Management that Ackman likes - check (he hired Joe Papa, B&L CEO, at Valeant/BHC)

-Size Parameters - check (if B&L valued on a consistent basis with peers, PSTH would own ~30% of B&L with $5bn and PS pro-rata ownership would be about ~5%; if upsized to $6bn PS would own c. 10%; that ownership stake and proceeds are consistent with what BHC needs to de-lever effectively)

B&L also meets all their other criteria (FCF +, durable growth business etc). Although Ackman has a tainted history with Pharma (Valeant), the eyecare business is far more stable and less susceptible to regulatory issues than true pharma businesses (which is why they trade at 23x+ EBITDA - lots of concumer product exposure) and he does have some history with it. Issue is Icahn is on the flip side of the transaction and they have a history - but really it's a "win-win" because it saves BHC the IPO discount for spinning out B&L and gives them greater liquidity than an IPO would out of the gate (could probably only list ~15-20% out of the gate). PSTH can probably take a view that they are getting it at a value that is impacted by COVID related performance. 

Curious as to views/thoughts from others... 

Note: I am long BHC and glta who are in a similar position.

PS - am surprised this board is not more active

Comment by SlumdogMillionaire on Jun 01, 2021 6:02pm
Interesting info, thanks for sharing. I'm long BHC too, they have lots of great products, rapidly improving debt situation and cash flow. Valuation looks quite cheap compared to peers.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities